Mood Changes and Aggression on TRT: What the Evidence Actually Shows

The "Roid Rage" Question: What Clinical Trials Actually Measured

The belief that testosterone causes aggression dates to case reports of anabolic steroid abusers in the 1980s and 1990s, where doses reached 10-100 times physiologic levels. TRT operates in a completely different pharmacologic range. The distinction matters.

In the Testosterone Trials (TTrials), 790 men aged 65 and older with serum testosterone below 275 ng/dL received either transdermal testosterone gel or placebo for 12 months [1]. The mood substudy used the Positive and Negative Affect Schedule (PANAS) and the Patient Health Questionnaire (PHQ-9) to track emotional changes. Men in the testosterone arm showed small but statistically significant improvements in depressive symptoms compared to placebo. No increase in aggression, hostility, or anger was documented across any validated behavioral instrument during the trial period.

A separate meta-analysis published in The Lancet Healthy Longevity (2022) pooled 35 randomized controlled trials of testosterone therapy and found no association between physiologic-dose testosterone and aggressive behavior [2]. The data consistently show that when total testosterone stays within the 400-700 ng/dL replacement window, behavioral side effects are rare.

Mood is not binary. Some men do report increased irritability in the first 4-8 weeks of TRT. This is real. But the mechanism typically involves rapid hormonal fluctuation rather than testosterone itself.

Why Some Men Feel Irritable Early in Treatment

The first weeks of TRT involve significant endocrine recalibration. Irritability during this window usually has a traceable physiologic cause, not a personality change.

Three mechanisms explain most early-onset mood disturbance. First, testosterone aromatizes to estradiol via the aromatase enzyme, and a rapid rise in estradiol can produce emotional lability, anxiety, and mood swings independently of testosterone's direct CNS effects. A 2017 study in the Journal of Clinical Endocrinology & Metabolism showed that estradiol levels above 40-50 pg/mL correlated with increased emotional reactivity in men on TRT [3]. Second, injection-based protocols with long intervals (biweekly cypionate, for example) create peak-trough cycles where testosterone spikes above 1 to 000 ng/dL at 48 hours post-injection and falls below baseline by day 12-14. These swings can mirror the irritability patterns seen in poorly managed hormonal states. Third, TRT can worsen or unmask obstructive sleep apnea (OSA), and sleep fragmentation is a potent independent driver of irritability and anger.

The clinical response to early irritability is protocol adjustment, not discontinuation. Splitting injection frequency from every 14 days to every 3.5 days flattens the pharmacokinetic curve. Checking sensitive estradiol (LC/MS method) at trough identifies whether aromatization is excessive. And screening with the STOP-BANG questionnaire catches undiagnosed OSA before it compounds mood symptoms.

TRT Side Effects Overview: Beyond Mood

Mood changes represent one dimension of TRT's side effect profile. The Endocrine Society's 2018 clinical practice guideline provides the most widely referenced framework for monitoring and managing treatment [4]. A complete understanding of TRT risk requires attention to hematologic, cardiovascular, and urologic endpoints.

Common side effects at physiologic doses include acne (particularly on the back and shoulders), increased body hair growth, testicular atrophy from HPG axis suppression, and fluid retention. Most are mild. Most are manageable with dose or protocol modification. The side effect that demands the most consistent surveillance, however, is erythrocytosis.

The TRAVERSE trial (N=5,246), the largest randomized cardiovascular safety trial of TRT ever conducted, confirmed that testosterone therapy did not increase the composite rate of major adverse cardiovascular events (MACE) compared to placebo over a mean follow-up of 33 months [5]. This was a significant finding because the FDA had mandated the trial after earlier observational studies raised cardiovascular safety signals. TRAVERSE largely resolved that concern for men aged 45-80 with hypogonadism and pre-existing or high risk of cardiovascular disease.

Erythrocytosis and Elevated Hematocrit on TRT

Erythrocytosis is the most common laboratory abnormality associated with TRT. Testosterone stimulates erythropoietin production and directly enhances erythroid progenitor cell proliferation in bone marrow. The result is a dose-dependent increase in red blood cell mass.

In TRAVERSE, the incidence of hematocrit exceeding 54% was approximately 7.5% in the testosterone group versus 2.9% in the placebo group [5]. A 2014 meta-analysis in Mayo Clinic Proceedings found that erythrocytosis was the most frequent adverse event across TRT trials, occurring at rates of 5-18% depending on formulation and dose [6]. Injectable testosterone cypionate and enanthate carry higher erythrocytosis risk than topical gels because of their higher peak concentrations.

Hematocrit above 54% increases blood viscosity and raises the risk of venous thromboembolism, stroke, and myocardial infarction. The Endocrine Society guideline recommends checking a complete blood count (CBC) at baseline, at 3-6 months, then annually [4]. If hematocrit exceeds 54%, the guideline calls for dose reduction, formulation change, or temporary discontinuation until levels normalize. Therapeutic phlebotomy (removing 1 unit of blood) provides rapid reduction but does not address the underlying dose-response relationship.

Dr. Shalender Bhasin, principal investigator of the TTrials, has noted: "The increase in hematocrit is the most predictable adverse effect of testosterone administration and requires systematic monitoring in every patient on long-term therapy" [1].

TRT and Prostate Cancer Risk: What TRAVERSE Settled

The fear that testosterone feeds prostate cancer traces to Charles Huggins' 1941 Nobel Prize-winning work demonstrating that castration caused prostate cancer regression [7]. For decades, clinicians extrapolated that adding testosterone must accelerate prostate cancer. That extrapolation was wrong.

The saturation model, proposed by Abraham Morgentaler in 2006, explains why: androgen receptors in prostate tissue reach full occupancy at relatively low serum testosterone levels (approximately 230-250 ng/dL) [8]. Above that threshold, additional testosterone does not produce additional receptor-mediated growth stimulation. This is why men with testosterone of 500 ng/dL do not have larger prostates or higher cancer rates than men at 300 ng/dL.

TRAVERSE provided the definitive trial-level evidence. Over 3.2 years, there was no statistically significant difference in prostate cancer incidence between the testosterone and placebo groups (hazard ratio 0.97 to 95% CI 0.51-1.84) [5]. PSA increases were modest (mean 0.3-0.5 ng/mL above placebo) and clinically insignificant in the aggregate.

The Endocrine Society still recommends PSA measurement at baseline, 3-6 months, and then per age-appropriate screening guidelines [4]. A PSA rise exceeding 1.4 ng/mL within 12 months or an absolute value above 4.0 ng/mL warrants urologic referral. But the blanket contraindication of TRT in men without active prostate cancer has been abandoned by every major guideline body.

TRT and Benign Prostatic Hyperplasia

BPH presents a more nuanced clinical picture than prostate cancer. Testosterone and its metabolite dihydrotestosterone (DHT) do influence prostate smooth muscle tone and glandular volume, and men with pre-existing BPH may experience worsening lower urinary tract symptoms (LUTS) on TRT.

A 2016 systematic review in the Journal of Urology examined 14 studies of TRT in men with BPH and found no significant change in International Prostate Symptom Score (IPSS) at physiologic doses in most trials [9]. However, a subset of men with moderate-to-severe baseline LUTS did report symptom worsening, particularly increased nocturia and weak stream.

Practical management involves obtaining baseline IPSS and uroflowmetry in men over 50 before starting TRT. If IPSS is above 19 (severe category), consider treating BPH pharmacologically with a 5-alpha reductase inhibitor or alpha-blocker before initiating testosterone. In men already stable on finasteride or dutasteride, TRT can generally proceed safely because the 5-alpha reductase inhibitor limits DHT conversion in prostate tissue. Check IPSS at each follow-up visit during the first year. A rise of 4 or more points warrants urologic evaluation.

Long-Term Psychological Effects: Depression, Cognition, and Quality of Life

Beyond the aggression question, TRT's effects on broader psychological function have been studied across several domains. Short answer: the benefits are real but modest, and they depend on baseline testosterone being genuinely low.

The TTrials vitality substudy reported a statistically significant improvement in the FACIT-Fatigue scale in the testosterone group, though the effect size was small [1]. A 2019 meta-analysis in JAMA Internal Medicine pooling 27 RCTs (N=3,092) found that TRT improved depressive symptom scores with a standardized mean difference of -0.21 (95% CI -0.31 to -0.11), a small but consistent effect across trials [10]. The benefit was most pronounced in men with baseline testosterone below 300 ng/dL and co-existing mild-to-moderate depression.

Cognitive effects have been less convincing. The TTrials cognition substudy found no improvement in memory or executive function at 12 months [1]. A Cochrane review (2022) reached a similar conclusion: insufficient evidence to support TRT for cognitive decline in aging men [11].

Quality of life measures, assessed by the SF-36 in multiple trials, show improvements in energy and physical function domains, with less consistent gains in emotional and social domains. Men who report the most dramatic quality-of-life improvements tend to be those with the most symptomatic hypogonadism at baseline, which reinforces the principle that TRT works best when there is a genuine deficit to correct.

Monitoring Protocol: Catching Problems Before They Become Symptoms

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and co-author of the Endocrine Society guideline, has stated: "The safety of testosterone therapy depends entirely on the quality of monitoring. An unmonitored patient on TRT is an at-risk patient" [4].

The Endocrine Society recommends the following surveillance schedule for men on TRT [4]: baseline labs (total testosterone, free testosterone, CBC, PSA, metabolic panel, lipid panel, estradiol), repeat testing at 6-12 weeks after initiation to assess trough testosterone and hematocrit, a 3-6 month comprehensive panel, then every 6-12 months thereafter. Bone density assessment (DXA) is recommended at 1-2 years for men with osteoporosis at baseline.

For mood-specific monitoring, no validated TRT-specific mood instrument exists. The PHQ-9 for depression and the GAD-7 for anxiety are practical screening tools at each visit. If a patient reports new irritability or mood lability, the differential should include: estradiol elevation (check sensitive E2), hematocrit above 54% (fatigue and headache mimic mood symptoms), sleep apnea worsening (STOP-BANG or polysomnography), and supraphysiologic dosing (check trough and peak levels).

Protocol adjustments that resolve most mood complaints include switching from biweekly to twice-weekly subcutaneous injections (typical dose: 50-80 mg testosterone cypionate per injection), reducing total weekly dose by 10-20% if trough testosterone exceeds 700 ng/dL, and addressing estradiol if levels exceed 40 pg/mL at trough. Aromatase inhibitors (anastrozole 0.25-0.5 mg twice weekly) remain controversial but are sometimes used short-term while body composition improves.

Men starting TRT with a hematocrit above 50% at baseline should be monitored at 4-week intervals until stability is confirmed, given their higher risk of crossing the 54% threshold.